{
    "clinical_study": {
        "@rank": "65666", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with\n      recurrent primary brain tumors following radiation therapy."
        }, 
        "brief_title": "Suramin in Treating Patients With Recurrent Primary Brain Tumors", 
        "completion_date": {
            "#text": "May 2004", 
            "@type": "Actual"
        }, 
        "condition": "Brain and Central Nervous System Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Nervous System Neoplasms", 
                "Central Nervous System Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Estimate the efficacy of suramin in patients with recurrent primary brain\n      tumors as measured by radiographic response, time to progression, and survival. II. Assess\n      the toxic effects of suramin in this patient population.\n\n      OUTLINE: Single-Agent Chemotherapy. Suramin, SUR, NSC-34936.\n\n      PROJECTED ACCRUAL: If at least 1 of the first 14 patients experiences at least a partial\n      response, a total of 25 patients will be entered over approximately 30 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Recurrent brain tumor based on one of the following: Tissue\n        diagnosis if there was a prior diagnosis of astrocytoma or oligodendroglioma or if there\n        is a question of radiation necrosis from prior interstitial brachytherapy Metabolic\n        activity in excess of normal cortex measured by 18-fluorodeoxyglucose uptake on PET One of\n        the following histologic types required: Glioblastoma multiforme Anaplastic astrocytoma\n        Anaplastic oligodendroglioma Anaplastic mixed glioma Tumor progression required, i.e.: 28%\n        increase in contrast-enhancing area or 50% increase in contrast- enhancing volume over at\n        least 4 weeks Measurable disease required No history, surgical findings, or radiographic\n        signs of intratumoral hemorrhage\n\n        PATIENT CHARACTERISTICS: Age: Over 15 Performance status: Karnofsky 50%-100% Life\n        expectancy: At least 12 weeks Hematopoietic: WBC at least 3,000 Platelets at least 75,000\n        Hepatic: Bilirubin less than 1.5 mg/dL AST/ALT less than 3 times normal No history of\n        bleeding disorder No hepatic disease resulting in hospitalization Renal: Creatinine less\n        than 1.5 mg/dL No renal disease resulting in hospitalization Cardiovascular: No ongoing\n        anticoagulation for deep vein thrombosis (DVT) No residual symptoms from DVT after\n        discontinuation of anticoagulation No cardiac disease resulting in hospitalization\n        Pulmonary: No pulmonary disease resulting in hospitalization Other: No peripheral\n        neuropathy of any etiology HIV negative No pregnant or nursing women Adequate\n        contraception required during and for 12 months following protocol therapy\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n        chemotherapy for glioblastoma multiforme No more than 1 prior chemotherapy regimen for\n        anaplastic astrocytoma, malignant oligodendroglioma, or malignant mixed glioma At least 4\n        weeks since chemotherapy (6 weeks since nitrosoureas or mitomycin) Endocrine therapy: Not\n        specified Radiotherapy: Completion of 1 course of conventional external radiotherapy\n        required At least 4 weeks since radiotherapy Surgery: Decompressive surgery for clinically\n        suspected increased intracranial pressure performed prior to entry"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002639", 
            "org_study_id": "CDR0000064118", 
            "secondary_id": [
                "EUC-DON-9420", 
                "NCI-T94-0033O"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "chemotherapy", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "suramin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Suramin"
        }, 
        "keyword": [
            "recurrent adult brain tumor", 
            "adult glioblastoma", 
            "adult anaplastic astrocytoma", 
            "adult anaplastic oligodendroglioma", 
            "adult mixed glioma", 
            "adult giant cell glioblastoma", 
            "adult gliosarcoma"
        ], 
        "lastchanged_date": "June 20, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EUC-DON-9420"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Atlanta", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30322"
                }, 
                "name": "Department of Neurosurgery - Emory"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "ANALYSIS OF THE EFFICACY OF SURAMIN IN RECURRENT MALIGNANT PRIMARY BRAIN TUMORS", 
        "overall_official": {
            "affiliation": "Winship Cancer Institute of Emory University", 
            "last_name": "Jeffrey J. Olson, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002639"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Winship Cancer Institute of Emory University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 1995", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2001"
    }, 
    "geocoordinates": {
        "Department of Neurosurgery - Emory": "33.749 -84.388"
    }
}